S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Alnylam Pharmaceuticals Announces Proposed Public Offering of $450 Million of Common Stock (2015/1/20)|
|Corporate Leaders Receive Fifteenth Annual Emerald Asset Management “E-3 Awards” (2015/2/9)|
|Alnylam and Isis Form New Agreement, Extending Decade-Long Partnership for Leadership in RNA Therapeutics (2015/1/9)|
|Alnylam Elects Michael W. Bonney to Its Board of Directors (2014/12/18)|
|New Paper in Journal of the American Chemical Society Documents Pioneering Discovery of GalNAc-Conjugated siRNA by Alnylam Scientists (2014/12/1)|
|Alnylam Launches “Alnylam 2020” Guidance for Advancement and Commercialization of RNAi Therapeutics (2015/1/8)|
|Alnylam and The Medicines Company Announce Initiation of Phase 1 Clinical Trial for ALN-PCSsc, a Subcutaneously Administered Investigational RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia (2014/12/11)|
|Alnylam Initiates Phase 1/2 Clinical Trial for ALN-CC5, a Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 in Development for the Treatment of Complement-Mediated Diseases (2015/2/2)|
|Alnylam Files Clinical Trial Application (CTA) for ALN-CC5, an RNAi Therapeutic Targeting Complement C5 in Development for the Treatment of Complement-Mediated Diseases (2014/12/7)|
|Alnylam Files Clinical Trial Application to Initiate a Phase 1 Study for ALN-AS1, a Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase-1 (ALAS-1) for the Treatment of Hepatic Porphyrias (2015/1/5)|
Click above to view more mutual fund data and stats for alny - Alnylam Pharmaceuticals Inc.